Medical Attributes of Symphytum officinale - Comfrey

By Justin Gentile and Nathaniel Lamoreaux
Wilkes University, Wilkes-Barre, PA

July, 2011

Symphytum officinale otherwise known as comfrey, knitbone, boneset, or blackwort, is a member of the Borage family (Boraginaceae). It is a large rooted perennial with large, rough, broadly oval leaves and puple-blue or pink bell-like flowers in furled clusters (Foster & Duke, 2000).  Comfrey is native to Europe and western Asia and has been introduced and is now naturalized in the eastern U.S. and Canada. It can usually be found growing along stream banks and in moist meadows (Foster & Johnson, 2008). While it prefers damp soils, it can be grown in good garden soil (Foster & Johnson, 2008).

Comfrey has been used since at least 400 B.C. Both Greek and Roman cultures utilized the plant in several different remedies. The Greek physician Dioscorides recommended comfrey for healing wounds and mending broken bones. Both civilizations made poultices from the leaves and roots to treat external wounds, while making comfrey tea for stomach ailments, internal bleeding, diarrhea, and other maladies. The plant was also used in the Middle Ages as a poultice and tea. During that time, the poultice was applied to fractures, bruises, and wounds while the tea was drunk to remedy internal injuries (Foster & Johnson, 2008). Comfrey remained a popular herbal remedy for those disorders as well as other various ailments including diarrhea, dysentery, bronchitis, tuberculosis, ulcers, and hemorrhoids for centuries (Foster & Johnson, 2008). Comfrey was also developed into ointments for application to bruises, sprains, strains, torn ligaments, burns, arthritis, and almost any kind of inflamed swelling. However, research began to surface in the 1970s and 1980s showing that all parts of the plant, and especially the roots, contain toxic pyrrolizidine (Foster & Duke, 2000). These findings have prompted countries such as the US, the United Kingdom, Australia, Canada, and Germany to ban all ingestible comfrey products. Since 2001, only preparations designed for topical use and some skin conditions have been approved for sale in the U.S. (Foster & Duke, 2000).

The roots of comfrey contain many chemicals including allantoin, mucopolysaccharides, flavones, steroidal saponins, pyrrolizidine alkaloids, and phenolic acids (mainly rosmarinic acid) (Roman, et. al 2008). Three of the primary chemicals, allantoin, pyrrolizidine alkaloids, and rosmarinic acid, have therapeutic characteristics.  Allantoin can cause cells to multiply, enhancing regeneration of damaged tissues. Rosmarinic acid is known as an anti-inflammatory. Pyrrolizidine alkaloids help stop bleeding, but have been shown to damage the liver and cause tumors in laboratory animals (Foster & Johnson, 2008). These alkaloids occur in a number of different families in areas all over the world. Their function is unknown, but their bitter taste most likely plays a role in deterring predators (McLean, 1970).

Research performed by Spin-Neto, et. al. (2008) involved implanting titanium rods in the tibiae of mature rats, and the subsequent monitoring of bone growth around them. Upon internal homeopathic treatment of S. officinale preparations, bone formation was enhanced significantly, especially during the early stages of osseointegration. This suggests that comfrey has tissue mending potential.

Comfrey has also been shown to promote wound healing and relieve inflammation. Barna, et al (2007) found that a topically applied preparation of 10% comfrey extract produced a faster initial reduction of wound sizes in patients after two to three days of application. Significant anti-inflammatory activity has also been demonstrated in vivo (Bradley, 1992).

Comfrey’s relationship with cancer is the subject of much debate.  Gomes, et. al (2010) gave 10% comfrey ethanolic extract orally to rats that had induced cancer by the resistant hepatocyte model (RHM).  Upon macroscopic/microscopic quantitative analysis, the authors found reductions in the number of pre-neoplastic macroscopic lesions, proliferating cell nuclear antigen positive cells, and acidophilic pre-neoplastic nodules, as well as a reduction in the percentage of cells in mitosis. Furthermore, the percentage of cells presenting megalocytosis and vacuolar degeneration was increased. This indicates a reduction of cell proliferation, suggesting possible anti-cancer potential for S. officinale. Another study by Roman, et al (2008) determined that total plant extracts exhibit cytostatic and mitoinhibitory properties of significant amplitude on HeLa neoplasic cells. The study attributes this inhibitory effect to phenolic acids, known to have anti-cancer and anti-oxidant properties, found in comfrey root extracts. In contrast, Stickel and Seitz (2000) found that endogenous pyrrolizidine alkaloids caused a substantial health hazard from hepatic toxicity in humans and carcinogenic potential in rodents. Those findings were supported by Mei, et al (2005), who found comfrey exhibited mutagenic properties in rat liver that were attributed to pyrrolizidine alkaloids. In addition, comfrey extracts were implicated as causing the destruction of small hepatic veins, known as veno-occlusive disease, leading to cirrhosis and liver failure (Stickel & Seitz, 2000).

The pyrrolizidine alkaloids (PA’s) found in comfrey are one of the leading plant toxins for animals and humans.  The Symphytum species produce a variety of PA’s, including echimidine, intermedine, lasiocarpine, lycopsamine, myoscorpine, symlandine, symphytine, and symviridine (Mei, et. al 2010).  Herbal remedies containing these alkaloids are reported to cause both mutations and cancer. Upon ingestion, the pyrrolizidine alkaloids are metabolized into highly reactive electrophiles in the liver, which react with cellular macromolecules forming adducts. The persistent nature of PA’s in animal tissue, along with modified DNA adducts which result, imply carcinogenic potential (Lewis, 2003). Mei, et. al (2010) suggests that the active metabolites interact with DNA in liver endothelial cells and hepatocytes, ultimately leading to damaged DNA (adducts), mutation induction, and carcinogenesis.

From Dioscorides’ De Materia Medica of ancient times to the naturopathic practices of today, S. officinale holds some therapeutic value, especially in preventing cancer cell proliferation, healing wounds, and reducing inflammation. However, the presence of pyrrolizidine alkaloids has brought many serious concerns to light, most importantly, their potential as a hepatotoxin, mutagen, and possible carcinogen. As a result, the use of comfrey products have either been banned or restricted to topical use in many areas of the world. Even though comfrey has harmful effects, proper knowledge and appropriate government regulation of this plant are essential for its continued medicinal use.


LITERATURE CITED

Barna, M., A. Kucera, M. Hladicova, & M. Kucera. 2007.  Wound healing effects of a Symphytum herb extract cream (Symphytum X Uplandicum NYMAN: ): Results of a randomized, controlled double-blind study.  Wien Med Wochenschr 157.21 (2007): 569-74.

Bradley, P.R. 1992.  British Herbal Compendium. Vol. 1

Foster, S. & J. A. Duke. 2000. A Field Guide to Medicinal Plants and Herbs of Eastern and Central North America. Boston: Houghton Mifflin.

Foster, S. & R. L. Johnson. 2008. Desk Reference to Nature's Medicine. Washington, D.C.: National Geographic.

Gomes, M.F., Massoco C. de Oliveira, J.G. Xavier, & L.V. Bonamin. 2010. Comfrey (Symphytum officinale. l.) and experimental hepatic carcinogenesis: A short-term carcinogenesis model study. Evidence Based Complementary and Alternative Medicine. 7: 197-202.

Lewis, W.H. & M. Elvin-Lewis. 2003. Medical Botany. 2nd ed. Hoboken, NJ: John Wiley and Sons.

McLean, E.K. 1970. The toxic actions of pyrrolizidine (Senecio) alkaloids.  Pharmacological Reviews 22: 429-483.

Mei, N., L. Guo, P.P. Fu, J.C. Fuscoe, & Y. Luan. 2010.  Metabolism, genotoxicity, and carcinogenicity of comfrey.  Journal of Toxicology and Environmental Health. 13: 509-26.

Mei, N., L. Guo, P.P. Fu, R.H. Heflich, & T. Chen. 2005. Mutagenicity of comfrey (Symphytum officinale) in rat liver.  British Journal of Cancer. 92(5):873-5.

Roman, G.P., E. Neagu, V. Moroeanu, & G.L. Radu. 2008. Concentration of Symphytum officinale extracts with cytostatic activity by tangential flow ultrafiltration.  Roumanian Biotechnological Letters 13: 4008-13.

Spin-Neto, R., M.M. Belluci, C.E. Sakakura, G. Scaf, M.T. Pepato, & E. Marcantonio. 2010.  Homeopathic Symphytum officinale increases removal torque and radiographic bone density around titanium implants in rats. Homeopathy. 99: 249-54.

Stickel, F., & H.K. Seitz. 2000.  The efficacy and safety of comfrey. Public Health Nutrition 3: 501-508.


This paper was developed as part of the BIO 368 - Medical Botany course offered at Wilkes University during the summer of 2011. Course instructor was Kenneth M. Klemow, Ph.D. (kklemow@wilkes.edu). The information contained herein is based on published sources, and is made available for academic purposes only. No warrantees, expressed or implied, are made about the medical usefulness or dangers associated with the plant species in question.

Return to Plant Summaries page


This page posted and maintained by Kenneth M. Klemow, Ph.D., Biology Department, Wilkes University, Wilkes-Barre, PA 18766. (570) 408-4758, kklemow@wilkes.edu.